Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
Holding AU:PTX?
Track your performance easily
PTX Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.04 - AU$0.11
Previous CloseAU$0.04
Volume74.17K
Average Volume (3M)610.11K
Market Cap
AU$31.41M
Enterprise ValueAU$20.73M
Total Cash (Recent Filing)AU$12.28M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Feb 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares OutstandingN/A
10 Day Avg. Volume1,035,387
30 Day Avg. Volume610,105
Standard Deviation0.28
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)120.05
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Prescient Therapeutics Limited News
PremiumCompany Announcements
Prescient Therapeutics CEO Set for 2025 Departure
PremiumCompany Announcements
Prescient Therapeutics Advises Investor Caution
PremiumCompany Announcements
Prescient Therapeutics Unveils Governance Statement
PremiumCompany Announcements
Prescient Therapeutics Reports Increased Revenue and Net LossPremiumCompany Announcements
Prescient Therapeutics Gains Momentum in PTX-100 TrialsPremiumCompany Announcements
Prescient Therapeutics Appoints New DirectorPremiumCompany Announcements
Prescient Therapeutics Options Expire Unexercised
PremiumCompany Announcements
Prescient Therapeutics Director’s Options ExpireOptions Prices
Currently, No data available
---
Ownership Overview
12.73%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
87.27% Public Companies and
Individual Investors
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.10 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Currently, no data Available
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Feb 21, 2025 which is in 154 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Aug 26, 2024. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 805,319,760 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
---
Prescient Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.87%
12-Months-Change
Fundamentals
Return on Equity
-37.32%
Trailing 12-Months
Asset Growth
-27.45%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia.
---
Technical Analysis
---